Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
VNDA
VNDA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VNDA News
Vanda Pharmaceuticals Under Investigation for Securities Fraud
2d ago
PRnewswire
Vanda Pharmaceuticals Q4 2025 Results Miss Estimates, Shares Drop 15%
3d ago
seekingalpha
Vanda Pharmaceuticals Plans to Raise $200 Million Through Securities Offerings
3d ago
stocktwits
Vanda Pharmaceuticals Releases 2026 Financial Objectives Amid Q4 Earnings Miss
4d ago
seekingalpha
Vanda Pharmaceuticals to Release 2025 Financial Results
Feb 04 2026
PRnewswire
Vanda Pharmaceuticals to Release 2025 Financial Results
Feb 04 2026
Newsfilter
Vanda Pharmaceuticals Under Investigation for Securities Fraud
Feb 03 2026
Globenewswire
Vanda Pharmaceuticals Under Investigation for Securities Fraud Claims
Jan 29 2026
PRnewswire
FDA Approves Zycubo for Pediatric Menkes Disease Treatment
Jan 28 2026
NASDAQ.COM
Vanda Pharmaceuticals Under Investigation After 14.05% Stock Drop Following FDA Decision
Jan 20 2026
Globenewswire
Vanda Pharmaceuticals' HETLIOZ® Faces Delay as FDA Rejects Current Efficacy Evidence
Jan 08 2026
Newsfilter
Vanda Pharmaceuticals Receives FDA Approval for Motion Sickness Drug, Analysts Raise Price Targets
Jan 06 2026
Newsfilter
Vanda Pharmaceuticals' Nereus Approved by FDA as First New Motion Sickness Drug in 40 Years
Jan 06 2026
Benzinga
ARS Pharma's Neffy Approved in China for Allergy Treatment
Jan 02 2026
NASDAQ.COM
Vanda Pharmaceuticals Receives FDA Approval, Shares Surge Over 25%
Jan 02 2026
Benzinga
US Stock Indices Decline as Chip Stocks Weaken
Jan 01 2026
NASDAQ.COM
Show More News
